Horizon Technology provides $50 million loan facility to Pelthos

Go back to Horizon Technology provides $50 million loan facility to Pelthos

Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics

January 15, 2026 4:10 PM UTC

FARMINGTON, Conn.--(BUSINESS WIRE)-- Horizon Technology Finance Corporation (NASDAQ: HRZN) (Horizon) (the Company), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (Pelthos), with an initial funding of $30 million, and up to $20 million to support future growth.

Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI (berdazimer) topical gel, an FDA-approved treatment of molluscum contagiosum, a common skin infection characterized by small bumps or lesions. ZELSUVMI delivers nitric oxide... More